NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 3 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
IRDAI ஒப்புதல்: Star Health-இல் HDFC Mutual Fund பங்கை 9.99% வரை உயர்த்த அனுமதி
Star Health and Allied Insurance Company நிறுவனம், HDFC Mutual Fund-இன் திட்டங்கள் நிறுவனத்தின் 9.99% வரையிலான பங்கு முதலீட்டைப் பெற IRDAI ஒப்புதல் அளித்துள்ளதாக அறிவித்துள்ளது. HDFC Mutual Fund தற்போது Star Health-இன் செலுத்தப்பட்ட பங்கு மூலதனத்தில் 4.49% பங்கு வைத்துள்ளது. இந்த ஒப்புதல், 5.50% வரை கூடுதல் பங்கு வாங்க வாய்ப்பளிக்கிறது. தற்போதைய ₹32,258 கோடி சந்தை மதிப்பின் அடிப்படையில் இது சுமார் ₹1,774 கோடி மதிப்புள்ள பங்குகளுக்குச் சமம்.
உச்சம் நம்பிக்கை
என்ன மாறியதுHDFC Mutual Fund-இன் Star Health பங்கு விகிதத்தை 4.49%இலிருந்து அதிகபட்சமாக 9.99% வரை உயர்த்த IRDAI ஒழுங்குமுறை ஒப்புதல் அளித்துள்ளது.
ஏன் இது முக்கியம்இந்தியாவின் மிகப்பெரிய உள்நாட்டு நிறுவன சொத்து மேலாண்மை நிறுவனங்களில் ஒன்று, புதிய பங்குகளை வெளியிட்டு பங்குகளை நீர்த்துப்போகச் செய்யாமலேயே Star Health-இல் தனது முதலீட்டை சாத்தியமாக இரட்டிப்பாக்க முடியும். இது நிறுவன முதலீட்டாளர்களின் நம்பிக்கையைக் காட்டுகிறது.
அனுமதிக்கப்பட்ட பங்கு உச்ச வரம்பு: 9.99%தற்போதைய முதலீடு: 4.49%அனுமதிக்கப்பட்ட கூடுதல் பங்கு விகிதம்: 5.50%5.5% கூடுதல் பங்கின் மதிப்பு (₹32,258 கோடி சந்தை மதிப்பில்): ~₹1,774 கோடி
📅 குறுகிய காலம்HDFC MF திட்டங்களிலிருந்து சாத்தியமான நிறுவன வாங்கல் தேவை உருவாகும் என்பதால், குறுகிய காலத்தில் பங்கு விலைக்கு நேர்மறையான ஆதரவு கிடைக்கக்கூடும்.
📈 நீண்ட காலம்நீண்ட காலத்தில் நிறுவன உரிமையின் நிலைத்தன்மையை இது மேம்படுத்தும். ஆனால் Star Health-இன் அடிப்படை அண்டர்ரைட்டிங் விகிதங்களையோ சில்லறை வணிக வளர்ச்சியையோ இது நேரடியாக மாற்றாது.
⚠ அபாய எச்சரிக்கைகள்
ஒழுங்குமுறை ஒப்புதல், HDFC Mutual Fund பங்குகளை வாங்க வேண்டும் என்று கட்டாயப்படுத்தாது. உண்மையான பங்கு அதிகரிப்பு நிதி மேலாளரின் முடிவைப் பொறுத்தது.
👀 கவனிக்க வேண்டியவை
HDFC Mutual Fund திட்டங்கள் இரண்டாம் நிலை சந்தை கொள்முதல் அல்லது பிளாக் டீல்கள் மூலம் அனுமதிக்கப்பட்ட 9.99% உச்ச வரம்பை நோக்கி பங்கு விகிதத்தை உயர்த்துகின்றனவா என்பதை வரவிருக்கும் காலாண்டு பங்குதாரர் அமைப்பு அறிக்கைகளில் கண்காணியுங்கள்.
Star Health Q2 FY27 Earnings Call: Underwriting Profit Hits ₹99 Cr, PAT Surges Over 3x to ₹265 Cr
Star Health released its Q2 & H1 FY27 earnings call transcript, highlighting its fifth consecutive quarter of underwriting improvement. For Q2 FY27, Gross Written Premium (GWP) grew 19% YoY to ₹5,275 crore, while underwriting results turned to a positive ₹99 crore from a loss of ₹40 crore in Q2 FY26. Reported PAT jumped over threefold to ₹265 crore for the quarter, and H1 FY27 PAT rose 57% YoY to ₹815 crore. The Combined Insurance Service Ratio (CISR) improved by 2.9% to 98% in Q2 FY27, driven by better risk selection and retail growth.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the formal transcript for the Q2 & H1 FY27 earnings conference call held on October 28, 2026.
ஏன் இது முக்கியம்Demonstrates sustained operational turnaround with underwriting profitability turning positive for five consecutive quarters and normalized annualized ROE expanding to 15.1% in H1 FY27.
📅 குறுகிய காலம்Informational filing documenting management commentary; the financial numbers were already largely reflected during the results announcement.
📈 நீண்ட காலம்The structural improvement in loss ratios, recalibration of unprofitable portfolios, and expansion of proprietary agency/D2C channels support sustained underwriting profitability.
⚠ அபாய எச்சரிக்கைகள்
Regulatory uncertainty regarding commission structures on multi-year policies (which represent ~50% of fresh business)
Potential medical inflation and hospital network pricing risks
👀 கவனிக்க வேண்டியவை
Track whether the combined ratio remains below 100% in upcoming quarters and monitor regulatory clarifications regarding distribution commission norms on multi-year policies.
Star Health Q2 FY27 PAT Jumps 233% to ₹265 Cr; Underwriting Profit Swings to ₹99 Cr
Star Health reported strong operational turnaround for Q2 FY27, with net profit surging 233% YoY to ₹265 Crores (Normalised PAT up 70% to ₹390 Crores). Gross Written Premium (GWP) grew 19% YoY to ₹5,275 Crores, driven by a 35% growth in fresh Retail Health premiums. Underwriting performance swung into positive territory with an underwriting profit of ₹99 Crores versus a ₹40 Crore loss in Q2 FY26. Combined Insurance Service Ratio (CISR) improved by 2.9 percentage points YoY to 98.0%, marking its fifth consecutive quarter of underwriting improvement.
உச்சம் நம்பிக்கை
என்ன மாறியதுStar Health posted a profitable underwriting performance of ₹99 Crores (versus a loss of ₹40 Crores last year) and expanded its agency network to 8.7 lakh agents.
ஏன் இது முக்கியம்Underwriting profits crossing below the 100% combined ratio threshold indicates core health insurance profitability independent of investment returns.
📅 குறுகிய காலம்The strong turnaround in underwriting profits and 233% reported PAT surge should be received positively by markets in upcoming trading sessions.
📈 நீண்ட காலம்Sustained sub-100% combined ratios and strong digital direct-to-consumer adoption (up 137% YoY in H1) support structural margin expansion and return metrics.
⚠ அபாய எச்சரிக்கைகள்
Medical claims inflation risk which could push claims ratios higher
Single-line insurance business exposure to unexpected seasonal health claim surges
👀 கவனிக்க வேண்டியவை
Track whether the sub-100% combined ratio (98.0%) remains sustainable through H2 FY27, particularly monitoring claims inflation and agency-led volume momentum.
Star Health Q2 FY27 Results: Profit After Tax at ₹264.4 Cr, Claims Ratio at 68.95%
Star Health reported its financial results for the quarter ended September 30, 2026, recording a Profit After Tax of ₹264.41 Cr compared to ₹814.54 Cr in the preceding quarter (Q1 FY27). Health segment insurance revenue for Q2 stood at ₹5,026.67 Cr, up from ₹4,340.20 Cr in Q2 FY26. For the half-year ended September 30, 2026, total insurance revenue reached ₹9,834.98 Cr with net profit at ₹1,078.95 Cr (H1 PAT ₹549.74 Cr). The company reported a claims ratio of 68.95% and an expense ratio of 23.01% for the quarter.
உச்சம் நம்பிக்கை
என்ன மாறியதுStar Health submitted its integrated financial results filing for the quarter and half-year ended September 30, 2026.
ஏன் இது முக்கியம்Demonstrates operating performance, underwriting profitability, and claims ratio management for India's largest standalone health insurer.
Q2 PAT: ₹264.41 கோடிQ2 Health Revenue: ₹5,026.67 கோடிClaims Ratio (Q2): 68.95%Expense Ratio (Q2): 23.01%Basic EPS (Q2): ₹4.50
📅 குறுகிய காலம்Market may assess underwriting profitability as claims ratio sits around 68.95%, remaining under the company's 70% margin-squeeze watch level.
📈 நீண்ட காலம்Performance reflects steady retail insurance growth and repricing benefits across the retail book, maintaining leadership among standalone health insurers.
⚠ அபாய எச்சரிக்கைகள்
Claims inflation risking underwriting margins if claims ratio breaches 70%
👀 கவனிக்க வேண்டியவை
Track the claims ratio trajectory relative to the management's 70% threshold and observe premium growth in the retail segment following product repricing.
Star Health Q1 FY27: PAT up 25% to ₹550 Cr, Underwriting Profit surges to ₹111 Cr
Star Health reported a strong Q1 FY27 with Gross Written Premium (GWP) growing 19% YoY to ₹4,287 crore. A significant highlight is the core underwriting profit, which jumped to ₹111 crore from just ₹16 crore in the same quarter last year, marking four consecutive quarters of improvement. Net profit rose 25% to ₹550 crore, while normalized PAT (at 8% yield) grew 44% to ₹386 crore. The company continues to expand its distribution, adding 20,000 agents to reach a total of 8.5 lakh.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has successfully transitioned to a higher underwriting profitability trajectory, moving from a near-break-even underwriting result a year ago to a robust ₹111 crore profit this quarter.
ஏன் இது முக்கியம்As India's largest standalone health insurer, Star Health's shift toward 'normalized' ROE of 15.6% (up from 12.2%) demonstrates that its strategy of repricing and risk-based underwriting is yielding financial results despite a slight dip in market share.
📅 குறுகிய காலம்The stock may react positively to the sharp improvement in underwriting results and the 44% growth in normalized PAT, indicating better operational efficiency.
📈 நீண்ட காலம்The company's focus on proprietary channels (90%+ of retail business) and digital sourcing (97% of new apps) provides a structural cost advantage and better control over claim outcomes over the long term.
⚠ அபாய எச்சரிக்கைகள்
Seasonal claims inflation from dengue/malaria in Q2
Market share compression (down to 29% from 31% YoY)
Regulatory shifts in Bancassurance impacting growth
👀 கவனிக்க வேண்டியவை
Watch for the sustainability of underwriting margins in Q2, which typically sees higher claims due to seasonal infectious diseases, and monitor if the retail market share (currently 29%) stabilizes after recent pricing corrections.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
25% PAT Growth to ₹550 Cr in Q1 FY27; Underwriting Profit Surges to ₹111 Cr
Star Health reported a strong Q1 FY27 with Profit After Tax (PAT) rising 25% YoY to ₹550 Cr, driven by a 19% growth in Gross Written Premium (GWP) to ₹4,287 Cr. The company achieved a significant turnaround in underwriting profitability, with the underwriting result jumping to ₹111 Cr from ₹16 Cr in the previous year. The Combined Insurance Service Ratio (CISR) improved to 97.0% from 98.7%, reflecting better cost management and a lower loss ratio of 67.5%. Retail fresh business grew by 37%, supported by a massive 142% growth in the D2C channel.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company transitioned from marginal underwriting profitability to a more substantial contribution (₹111 Cr) while maintaining high double-digit premium growth and improving its loss ratio.
ஏன் இது முக்கியம்Improved underwriting margins and lower loss ratios (67.5% vs 68.5%) indicate better risk selection and operational efficiency, which are critical for a standalone health insurer's long-term ROE and valuation.
PAT (Q1 FY27): ₹550 கோடிGWP Growth (YoY): 19%Underwriting Result: ₹111 கோடிCombined Insurance Service Ratio: 97.0%D2C Fresh GWP Growth: 142%PAT vs TTM PAT: 98.7%
📅 குறுகிய காலம்Positive market reaction is likely as the company beat underwriting expectations and showed strong growth in fresh retail premiums.
📈 நீண்ட காலம்Structural improvement in the distribution mix (D2C growth) and agency productivity (8.5 lakh agents) could lead to sustained ROE expansion, which was 22.3% (annualized) this quarter.
⚠ அபாய எச்சரிக்கைகள்
Dependency on hospital network pricing
Potential claims inflation if loss ratios revert above 70%
Regulatory shifts in Banca growth channels
👀 கவனிக்க வேண்டியவை
Monitor the sustainability of the improved CISR (below 100% indicates underwriting profit) and the growth trajectory of the high-margin D2C channel, which grew 142% YoY.
Rs 438 Cr Q1 PAT: Star Health Adopts Ind AS Accounting Standards
Star Health reported a flat Net Profit of Rs 438.18 Cr for Q1 FY27, matching the restated Ind AS profit from the same quarter last year. Insurance revenue grew 13.4% YoY to Rs 4,917.20 Cr. This quarter marks the mandatory transition to Ind AS 117 (Insurance Contracts) and Ind AS 109 (Financial Instruments), which significantly alters how liabilities and financial assets are valued. The company noted that seasonality, particularly the monsoon, typically leads to higher claims in the upcoming months.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company transitioned its financial reporting from Indian GAAP to Ind AS, specifically adopting Ind AS 117 for insurance contracts and Ind AS 109 for financial instruments.
ஏன் இது முக்கியம்The transition to Ind AS 117 is a major structural change in how insurance companies recognize revenue and liabilities, aligning Star Health with global accounting standards and providing a more granular view of insurance service results.
📅 குறுகிய காலம்The stock may see neutral to slightly cautious sentiment as the market adjusts to the new Ind AS reporting format and the flat YoY profit performance.
📈 நீண்ட காலம்The adoption of Ind AS 117 provides better transparency into the profitability of the insurance book over time, though the company's focus on retail health and agent expansion remains the primary long-term growth driver.
⚠ அபாய எச்சரிக்கைகள்
Seasonality (higher claims expected in monsoon)
Claims inflation
Accounting complexity during Ind AS transition
👀 கவனிக்க வேண்டியவை
Investors should focus on the 'Combined Ratio' and claims performance in the next quarter (Q2), as the company explicitly flagged higher seasonal claims during the monsoon. Monitor how the transition to Ind AS 117 affects long-term margin reporting.
Star Health Q1 Revenue Up 13.4% YoY to Rs 4,917 Cr; 4,700 NCDs to be Redeemed
Star Health reported Q1 FY27 insurance revenue of Rs 4,917.2 Cr, a 13.4% increase from Rs 4,336.4 Cr in the same quarter last year. Incurred claims for the quarter stood at Rs 2,951.4 Cr, reflecting a claims-to-revenue ratio of approximately 60%. The board also approved the full redemption of 4,700 listed NCDs in two tranches by October 2026 and initiated the reclassification of 97 promoter group entities (including the Estate of Late Rakesh Jhunjhunwala) to the public category.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company released its Q1 FY27 financial results, set a timeline for debt redemption, and began simplifying its promoter shareholding structure.
ஏன் இது முக்கியம்The results show steady top-line growth in the retail health segment, while the NCD redemption will reduce future interest obligations and the promoter reclassification cleans up the cap table.
📅 குறுகிய காலம்The stock may see neutral to slightly positive movement as the market digests the 13.4% revenue growth and the impact of debt reduction.
📈 நீண்ட காலம்The company's focus on expanding its agent network to 1 million and maintaining its 32-33% retail health market share remains the primary long-term value driver.
⚠ அபாய எச்சரிக்கைகள்
Claims inflation
High P/E ratio of 63.0 relative to historical PAT growth
Regulatory shifts in banking distribution (Banca growth)
👀 கவனிக்க வேண்டியவை
Investors should monitor the full financial statement to assess the Combined Ratio and Net Profit Margin, as the current revenue growth of 13.4% is slightly below the company's long-term target of 16%.
Star Health Approves Transmission of 8.28 Cr Shares & Board Reconstitution
Star Health has approved the transmission of 8,28,82,958 equity shares held by the late Mr. Rakesh Jhunjhunwala to his estate following a court probate. In a related move, Mr. Utpal Sheth resigned as the nominee director for the Jhunjhunwala estate and was immediately appointed as an Additional Director representing the promoter, Sitara Partners LLP. Additionally, two independent directors, Mr. Rajeev Agarwal and Ms. Rajni Sibal, are scheduled to retire on July 15, 2026, after completing their five-year terms. These changes formalize the shareholding transition while maintaining leadership continuity on the board.
முக்கிய அம்சங்கள்
Transmission of 8,28,82,958 equity shares from the estate of the late Mr. Rakesh Jhunjhunwala approved.Mr. Utpal Sheth appointed as Additional Director representing Sitara Partners LLP (Promoter).Retirement of Independent Directors Mr. Rajeev Agarwal and Ms. Rajni Sibal effective July 15, 2026.Mr. Utpal Sheth's appointment follows IRDAI approval received on April 06, 2026.The board meeting concluded within 15 minutes, indicating a focused agenda on procedural transitions.
👀 கவனிக்க வேண்டியவை
Investors should view this as a routine formalization of shareholding and board seats following the passing of a major investor. No immediate action is required as the transition ensures continuity of experienced leadership.
Star Health Shareholders Approve Promoter Reclassification and Director Remuneration Revisions
Star Health and Allied Insurance Company Limited has announced the results of its postal ballot, where shareholders approved eight key resolutions. A major highlight is the approval of the reclassification of certain 'promoter/promoter group' entities to the 'public' category with 99.99% support. Shareholders also greenlit remuneration revisions for the MD & CEO, Anand Roy, and other Whole-time Directors for FY 2026-27, alongside the continuation of Sumir Chadha as a Nominee Director.
முக்கிய அம்சங்கள்
Reclassification of promoter/promoter group to public category approved with 99.99% of valid votes.Remuneration revisions for MD & CEO Anand Roy and two Whole-time Directors for FY 2026-27 passed with 99.35% approval.Continuation of Mr. Sumir Chadha as Nominee Director of Safecrop Investments India LLP approved with 93.76% votes.Remuneration for Chairperson Rajeev Kher and Independent Directors approved with over 99.8% majority.The e-voting process saw participation from over 600 members for various resolutions.
👀 கவனிக்க வேண்டியவை
Investors should note the high level of shareholder consensus on management compensation and structural changes; no immediate action is required as these are standard governance procedures.
Star Health FY26 PAT Rises 16% to ₹911 Cr; GWP Crosses ₹20,000 Cr Milestone
Star Health reported a strong financial performance for FY26, with Gross Written Premium (GWP) growing 16% to ₹20,369 crore. The company achieved a significant turnaround in underwriting, posting a profit of ₹206 crore compared to a loss of ₹165 crore in FY25. Net profit (PAT) increased 16% YoY to ₹911 crore, while normalized PAT (at 8% yield) surged 45% to ₹1,222 crore. The combined ratio improved to 98.8% from 101.1%, reflecting better loss management and operating leverage.
முக்கிய அம்சங்கள்
Gross Written Premium (GWP) grew 16% YoY to ₹20,369 crore, crossing a major milestone.Combined ratio improved by 230 basis points to 98.8% in FY26 from 101.1% in FY25.Loss ratio saw a 200 bps improvement to 68.7% for the full year, with Q4 loss ratio at 65.2%.Maintained dominant retail market share of 31.3% with 90% of retail business from proprietary channels.Normalized Return on Equity (ROE) expanded significantly to 13.1% in FY26 from 10.1% in FY25.
👀 கவனிக்க வேண்டியவை
Investors should take note of the successful turnaround in underwriting profitability and the consistent improvement in loss ratios across quarters. The company's market leadership and shift towards a more profitable retail mix make it a strong play in the expanding health insurance sector.
Star Health FY26 PAT Rises 16% to ₹911 Cr; Combined Ratio Improves to 98.8%
Star Health reported a steady performance for FY26, with Gross Written Premium growing 16% YoY to ₹20,369 crore. The company's profitability improved, with IND AS PAT rising 16% to ₹911 crore and normalized PAT jumping 45% to ₹1,222 crore. Operational efficiency was evident as the combined ratio improved from 101.1% to 98.8%, driven by a lower loss ratio of 68.7%. Despite a Q4 loss due to significant mark-to-market investment hits, the core underwriting business remains robust with a 99% renewal ratio.
முக்கிய அம்சங்கள்
Gross Written Premium (GWP) grew 16% YoY to ₹20,369 crore in FY26.Combined Ratio improved significantly to 98.8% from 101.1% in the previous year.Retail health renewal ratio reached a high of 99%, up from 97% in FY25.Agency network expanded to 8.3 lakh agents, contributing to 37% fresh retail growth.Solvency ratio remains strong at 2.05x, well above the regulatory requirement.
👀 கவனிக்க வேண்டியவை
Investors should focus on the improving combined ratio and strong renewal persistency, which indicate high customer loyalty and better underwriting. The Q4 loss is primarily due to non-cash MTM investment adjustments rather than core business weakness.
Star Health FY26 PAT at ₹645.86 Cr; Gross Premium Grows 9.7% to ₹16,741 Cr
Star Health reported a standalone Net Profit of ₹645.86 crore for FY26, a decline from ₹750.98 crore in the previous fiscal year. Despite the annual profit dip, Gross Premium income showed steady growth, rising 9.7% YoY to reach ₹16,741 crore. The company's solvency ratio remains healthy at 2.05, well above the regulatory requirement, though the combined ratio increased slightly to 102.07%, indicating higher claims and operating costs.
முக்கிய அம்சங்கள்
Gross Premium income increased to ₹16,741 crore in FY26 compared to ₹15,251 crore in FY25.Full-year Net Profit (PAT) stood at ₹645.86 crore, down approximately 14% from ₹750.98 crore YoY.Solvency ratio remains robust at 2.05x, providing a significant cushion over the 1.50x regulatory mandate.Combined ratio, a key profitability metric, rose to 102.07% from 100.47% in the previous year.Earnings Per Share (EPS) for the full year decreased to ₹9.47 from ₹11.01 in FY25.
👀 கவனிக்க வேண்டியவை
Investors should monitor the rising combined ratio and its impact on underwriting margins despite steady premium growth. The stock remains a watch as the company balances market share expansion with bottom-line profitability.
Star Health's AA+ Issuer Rating Reaffirmed by Care Ratings with Stable Outlook
Care Ratings Limited has reaffirmed the credit ratings for Star Health and Allied Insurance Company Limited, signaling continued financial stability. The company's issuer rating remains at 'AA+' with a Stable outlook, while its subordinate debt rating is maintained at 'AA' with a Stable outlook. This reaffirmation reflects the rating agency's confidence in the insurer's creditworthiness and ability to service its debt obligations. The disclosure was made in compliance with SEBI Listing Obligations and Disclosure Requirements.
முக்கிய அம்சங்கள்
Care Ratings reaffirmed the Issuer Rating at AA+ with a Stable outlook.The rating for the company's subordinate debt was reaffirmed at AA with a Stable outlook.The announcement confirms compliance with SEBI Regulations 30 and 55.Ratings reaffirmation indicates a consistent credit profile and financial health for the insurer.
👀 கவனிக்க வேண்டியவை
Investors should take this as a positive sign of the company's credit strength and financial stability. No immediate portfolio changes are necessary as the ratings remain unchanged from previous levels.
Star Health Appoints Himanshu Walia and Amitabh Jain as Whole-time Directors for 5 Years
Star Health has received IRDAI approval to appoint Mr. Himanshu Walia and Mr. Amitabh Jain as Whole-time Directors and Key Managerial Personnel for a five-year term starting February 11, 2026. Mr. Walia, the current Chief Marketing Officer, has been with the company since 2007 and brings over 22 years of insurance experience. Mr. Jain, the current Chief Operating Officer and a former founding member of ICICI Lombard, has over 25 years of experience in financial services. These appointments strengthen the leadership team by elevating experienced internal executives to the board level.
முக்கிய அம்சங்கள்
Appointment of two Whole-time Directors for a fixed term of 5 years effective February 11, 2026Mr. Himanshu Walia (CMO) brings 22+ years of experience and has been with Star Health since 2007Mr. Amitabh Jain (COO) has 25+ years of experience and was a founding member of ICICI LombardAppointments have received formal regulatory approval from IRDAI
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive move for leadership continuity and operational stability. Monitor the company's execution on digital transformation and market share growth under this strengthened leadership team.
Star Health Q3 FY26 PAT Jumps to ₹449 Cr; Combined Ratio Improves to 98.9%
Star Health reported a robust Q3 FY2026 with Gross Written Premium (GWP) increasing 23% YoY to ₹5,047 crore, supported by a 45% surge in fresh business. Profit After Tax (PAT) under IND AS rose significantly to ₹449 crore from ₹87 crore in the previous year, driven by a 320 bps improvement in the combined ratio to 98.9%. The company maintained its market leadership with a 31.3% retail health market share and improved its 9M PAT by 87% YoY to ₹966 crore. Management highlighted a strategic shift towards high-margin retail business, which now constitutes 95% of the total portfolio.
முக்கிய அம்சங்கள்
Q3 GWP grew 23% YoY to ₹5,047 crore, with fresh business growth at 45% and renewal growth at 17%.Combined ratio improved by 320 bps YoY to 98.9% in Q3 FY26, leading to an underwriting profit of ₹46 crore.9M FY26 PAT increased 87% YoY to ₹966 crore, supported by an investment yield of 9.6%.Retail loss ratio decreased to 68.4% in Q3 FY26, down 103 bps from the previous year.Digital D2C channel grew 35% YoY in 9M FY26, contributing 20% of all fresh business premiums.
👀 கவனிக்க வேண்டியவை
Investors should note the significant operational turnaround as the company achieved underwriting profitability and a sub-100% combined ratio. The strong growth in the high-margin retail and digital segments, coupled with disciplined claims management, makes the stock a strong play on the expanding Indian health insurance sector.
Star Health Q3 FY26 PAT Surges 414% YoY to ₹449 Cr; Combined Ratio Improves to 98.9%
Star Health reported a massive 414% YoY growth in Profit After Tax (PAT) to ₹449 crore for Q3 FY26, driven by strong premium growth and improved operational efficiency. The Gross Written Premium (GWP) grew 23% YoY to ₹5,047 crore, with the retail segment showing a robust 27% growth. A significant improvement was seen in the Combined Ratio, which dropped to 98.9% from 102.1% a year ago, primarily due to a 301 bps reduction in the Loss Ratio. Investment income also played a crucial role, jumping 176% YoY to ₹569 crore.
முக்கிய அம்சங்கள்
Q3 PAT grew 414% YoY to ₹449 Cr, while 9M PAT rose 87% to ₹966 CrGross Written Premium (GWP) increased 23% YoY to ₹5,047 Cr in Q3 FY26Combined Ratio improved by 317 bps to 98.9%, indicating underwriting profitabilityRetail GWP grew 27% YoY to ₹4,838 Cr, maintaining a 31.3% market share in the retail segmentInvestment income surged 176% YoY to ₹569 Cr in Q3 FY26
👀 கவனிக்க வேண்டியவை
The strong improvement in the combined ratio below 100% and robust retail growth signal a turnaround in underwriting profitability. Investors should monitor the sustainability of the loss ratio moderation and the impact of the transition to Ind AS reporting.
Star Health 9M FY26 PAT Jumps 87% to ₹966 Cr; Combined Ratio Improves to 99.8%
Star Health reported a robust 87% YoY increase in Profit After Tax (PAT) to ₹966 crore for 9M FY26, supported by higher investment income and improved underwriting. Gross Written Premium (GWP) rose 16% to ₹13,856 crore, with the core retail segment growing at 20%. The combined ratio improved to 99.8% from 102.1% YoY, reflecting better expense management and lower loss ratios. However, fresh GWP from the bancassurance channel declined by 8% during the period.
முக்கிய அம்சங்கள்
Net Profit (PAT) surged 87% YoY to ₹966 crore in 9M FY26 compared to ₹516 crore in 9M FY25Combined Ratio improved to 99.8%, signaling a shift towards underwriting profitabilityRetail Health GWP reached ₹13,170 crore, representing a 20% YoY growth and 31% market shareInvestment income grew to ₹1,320 crore with an annualized yield of 9.6%Renewal ratio (persistency) strengthened significantly to 99% compared to 95% in 9M FY25
👀 கவனிக்க வேண்டியவை
The stock remains a strong play on the Indian health insurance sector given its market leadership and improving operational metrics. Investors should monitor the sustainability of the combined ratio below 100% and the recovery in the bancassurance channel.
Star Health Q3 FY26 PAT Drops 40% YoY to ₹128 Cr Despite 16.5% Premium Growth
Star Health and Allied Insurance reported a significant 40.4% year-on-year decline in Profit After Tax (PAT) to ₹128.22 crore for the quarter ended December 31, 2025. While Gross Written Premium grew by 16.5% to ₹4,423.43 crore, the bottom line was pressured by a rising combined ratio, which reached 94.31% compared to 92.51% in the previous year. On a positive note, the claims ratio improved to 68.55% from 70.30% YoY. The company also announced the reclassification of two promoter group entities with zero shareholding to the public category.
முக்கிய அம்சங்கள்
Gross Written Premium (GWP) increased 16.5% YoY to ₹4,423.43 crore in Q3 FY26.Profit After Tax (PAT) fell sharply to ₹128.22 crore from ₹215.14 crore in Q3 FY25.Combined Ratio deteriorated to 94.31% from 92.51% YoY, indicating higher operating costs.Claims Ratio showed improvement, declining to 68.55% from 70.30% in the same quarter last year.Solvency Ratio remains strong at 2.14x, significantly above the regulatory minimum of 1.50x.
👀 கவனிக்க வேண்டியவை
Investors should be cautious as the sharp decline in profitability despite strong top-line growth suggests rising operational pressures. Monitor management commentary regarding the increase in the combined ratio and strategies for margin recovery.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
